Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1276398 | 0.99 | ALDH1A1 (0.43) | ALDH1A1PDE4ALMNAUSP2SLCO1B1 | |
| SCHEMBL27610615 | 0.95 | ALDH1A1 (0.38) | ALDH1A1PDE4ALMNA | |
| Ammonia Solution, Strong SCHEMBL27487390 | 0.92 | PDE4A (0.43) | ALDH1A1PDE4ALMNAUSP2SLCO1B1 | |
| SCHEMBL28102458 | 0.85 | ALDH1A1 (0.54) | ALDH1A1LMNA | |
| SCHEMBL28469038 | 0.84 | PDE4A (0.37) | PDE4ALMNA | |
| SCHEMBL27675763 | 0.83 | ALDH1A1 (0.56) | ALDH1A1LMNA | |
| SCHEMBL4280799 | 0.83 | ALDH1A1 (0.44) | ALDH1A1PDE4ALMNAUSP2SLCO1B1 | |
| SCHEMBL5355291 | 0.83 | ALDH1A1 (0.44) | ALDH1A1PDE4ALMNAUSP2SLCO1B1 | |
| Citric Acid SCHEMBL9052947 | 0.82 | PDE4A (0.63) | ALDH1A1PDE4ALMNAUSP2SLCO1B1 | |
| SCHEMBL27518495 | 0.82 | ALDH1A1 (0.38) | ALDH1A1PDE4ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115259207-B | Preparation method of fourteen-surface cuprous oxide | 西北工业大学 | 2024-02-23 | — | — | CN | disclosed |
| CN-113621026-B | Polypeptide and application thereof in preparation of medicines for treating thrombocytosis or resisting tumor metastasis | 苏州大学 | 2023-04-25 | — | — | CN | disclosed |
| CN-115259207-A | Preparation method of tetradecahedron cuprous oxide | 西北工业大学 | 2022-11-01 | — | — | CN | disclosed |
| CN-113621026-A | Polypeptide and application thereof in preparing medicine for treating thrombocytosis or resisting tumor metastasis | 苏州大学 | 2021-11-09 | — | — | CN | disclosed |
| CN-111934043-B | Recovery process of waste lead-acid storage battery lead plaster | 湖南省长城新能源科技有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-107047538-B | Application of protein kinase A activator in platelet preservation and platelet preservation method | 苏州大学 | 2021-04-13 | — | — | CN | disclosed |
| CN-111934043-A | Recovery process of waste lead-acid storage battery lead plaster | 湖南省长城新能源科技有限公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-106943336-B | PRP/phospholipid liposome transdermal preparation and preparation method thereof | 西南医科大学 | 2020-04-03 | — | — | CN | disclosed |
| CN-110079558-A | With the method for 61 polypeptide pre-treating cellulosic material of family | 诺维信股份有限公司 | 2019-08-02 | — | — | CN | disclosed |
| CN-109402001-A | A kind of addition sodium citrate promotes the method and its application of pseudomonas aeruginosa degradation pyrene | 广东轻工职业技术学院 | 2019-03-01 | — | — | CN | disclosed |
| CN-104145016-B | Polypeptides having β -xylosidase activity and polynucleotides encoding same | 诺维信股份有限公司 | 2018-08-21 | — | — | CN | disclosed |
| CN-104126007-B | Polypeptide with catalase activity and the polynucleotides for encoding the polypeptide | 诺维信股份有限公司 | 2018-07-10 | — | — | CN | disclosed |
| CN-107708713-A | Treatment of cancer using recall antigens delivered by attenuated bacteria | 阿尔伯特爱因斯坦医学院公司 | 2018-02-16 | — | — | CN | disclosed |
| CN-106943336-A | A kind of PRP/ phospholipid liposomes preparation capable of permeating skin and preparation method thereof | 西南医科大学 | 2017-07-14 | — | — | CN | disclosed |
| US-20150153357-A1 | Compositions, Methods for Treatment, and Diagnoses of Autoimmunity-Related Disorders and Methods for Making Such Compositions | EIGER HEALTH PARTNERS, LLC | 2015-06-04 | — | — | US | disclosed |
| EP-2490721-A1 | COMPOSITIONS, METHODS FOR TREATMENT, AND DIAGNOSES OF AUTOIMMUNITY-RELATED DISORDERS AND METHODS FOR MAKING SUCH COMPOSITIONS | Eiger Health Partners, LLC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20110097344-A1 | Compositions, Methods for Treatment, and Diagnoses of Autoimmunity-Related Disorders and Methods for Making Such Compositions | EIGER HEALTH PARTNERS, LLC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2011050259-A1 | COMPOSITIONS, METHODS FOR TREATMENT, AND DIAGNOSES OF AUTOIMMUNITY-RELATED DISORDERS AND METHODS FOR MAKING SUCH COMPOSITIONS | EIGER HEALTH PARTNERS, LLC (US) | 2011-04-28 | — | — | WO | disclosed |
| CN-1823870-A | Celastrus orbiculatus ready prepared Chinese medicine and its application in resisting rheumatoid disease | UNIV NANFANG MEDICAL (CN) | 2006-08-30 | — | — | CN | disclosed |
| CN-1246815-A | Process for purifying substances polluted with organohalogen compounds | EBARA CORP (JP) | 2000-03-08 | — | — | CN | disclosed |